Satiety in Healthy VolunteersNCT07362563
Effect of Prebiotic Sodas on Postprandial Levels of GLP-1, PYY, Transit Time and Satiety Levels: A Pilot Study
A study testing Prebiotic Soda - Shelf Stable, Prebiotic Soda - Refrigerated and Prebiotic Soda - Shelf Stable + Functional Ingredient in people with Satiety in Healthy Volunteers, run by Olipop, PBC at 1 site in Canada.
Trial summary
The main objective of this study is to evaluate the acute effects of prebiotic sodas on postprandial levels of glucagon-like peptide-1 (GLP-1), peptide YY (PYY), gastric emptying, and satiety levels in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Satiety in Healthy Volunteers
- What is being tested?
- Prebiotic Soda - Shelf Stable, Prebiotic Soda - Refrigerated and Prebiotic Soda - Shelf Stable + Functional Ingredient
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteCanada
- Study dates
- 2 Feb 2026to 16 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18-60 years, inclusive.
- BMI between 18.0 and 30.0 kg/m2.
- Stable weight in the last 3 months (+/-5kg).
- Willing to abstain from unusual strenuous exercise, consuming alcoholic drinks and from taking fiber supplements for 24 hours before study days.
- Willing to refrain from smoking tobacco or e-cigarettes, and using marijuana in any form for 12h before and during study visits.
- Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
- Subjects must be eligible to receive income in Canada and be covered by a health insurance plan such as Ontario Health Insurance Plan (OHIP).
Who cannot join
- Self-reported pregnant or breastfeeding women.
- Subjects with a history of severe food allergies or an allergy to acetaminophen.
- Known history of diabetes, any gastrointestinal disorder that alters the absorption of nutrients, liver disease, or the presence of any health condition, illness or drug use that increases risk to the subject or to others or may affect the results, as judged by the Qualified Investigator (QI).
- Subjects who are currently or in the last 2 months have been on oral or injectable GLP-1 receptor agonist (RA) medications.
- Subjects who consume more than 14 alcoholic drinks per week, or more than 5 alcoholic drinks on any one occasion.
- Subjects who have been on antibiotic therapy in the last 2 months.
Show all 11Show fewer
- Subjects taking the blood thinning drug warfarin.
- Subjects who are habitual users of the following supplements in the past 30 days: berberine, curcumin, cinnamon, resveratrol, and gardenia.
- Subjects which have undergone major surgery in the last 3 months.
- Unwillingness or inability to comply with experimental procedures and to follow Inquis safety guidelines.
- Subject is currently participating or recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement, or lifestyle modification.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of 3 Different Prebiotic Sodas on Postprandial Levels of GLP-1, PYY, Transit Time and Satiety Levels: An Acute, Randomized Controlled Pilot Study in Healthy Participants
The main objective of this study is to evaluate the acute effects of prebiotic sodas on postprandial levels of glucagon-like peptide-1 (GLP-1), peptide YY (PYY), gastric emptying, and satiety levels in healthy adults.
Read the detailed description
The primary aim of this clinical trial is to evaluate the effects of single-dose prebiotic sodas on on postprandial levels of GLP-1.
Participants (n=15) will be healthy males and healthy, non-pregnant, non-lactating females aged 18-60 years. Participants will consume a single dose of 3 different prebiotic sodas (6 - 9 g dietary fiber and 4 g total sugar per can) and one control soda (0 g dietary fiber and 4 g total sugar per can) in a randomized, crossover design over a period of 4-12 weeks with an interval of at least 1 week and at most 3 weeks between visits.
Secondary outcomes will include evaluating the effects of single-dose consumption of the control and prebiotic sodas on postprandial PYY, gastric emptying, and satiety levels.
- Conditions
- Satiety in Healthy Volunteers
- Being tested
- Control Soda, Prebiotic Soda - Shelf Stable, Prebiotic Soda - Refrigerated, Prebiotic Soda - Shelf Stable + Functional Ingredient
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Control SodaOther
Participants will consume one 12 oz can of a control soda that contains 0 g dietary fiber and 4 g total sugar.
Prebiotic Soda - Shelf StableOther
Participants will consume one 12 oz can of a shelf stable prebiotic soda that contains 6 g dietary fiber and 4 g total sugar.
Prebiotic Soda - RefrigeratedOther
Participants will consume one 12 oz can of a shelf stable prebiotic soda that contains 9 g dietary fiber and 4 g total sugar.
Prebiotic Soda - Shelf Stable + Functional IngredientOther
Participants will consume one 12 oz can of a shelf stable prebiotic soda that contains 6 g dietary fiber, 4 g total sugar, and an added functional ingredient.
| Study group | Role | What they receive |
|---|---|---|
| Control Soda | Placebo comparator | Participants will consume one 12 oz can of a control soda Receives: Other: Control Soda |
| Prebiotic Soda - Shelf Stable | Experimental | Participants will consume one 12 oz can of the shelf stable prebiotic soda Receives: Other: Prebiotic Soda - Shelf Stable |
| Prebiotic Soda - Refrigerated | Experimental | Participants will consume one 12 oz can of the refrigerated prebiotic soda Receives: Other: Prebiotic Soda - Refrigerated |
| Prebiotic Soda - Shelf Stable + Functional Ingredient | Experimental | Participants will consume one 12 oz can of the shelf stable prebiotic soda with an added functional ingredient Receives: Other: Prebiotic Soda - Shelf Stable + Functional Ingredient |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood GLP-1 iAUC
Incremental area under the curve (iAUC) for GLP-1 from immediately prior to test-product consumption (t=0) to t=120 min following test-product consumption.
Measured: For 2 hours post intervention
Secondary outcomes (3)
Blood PYY iAUC
Incremental area under the curve (iAUC) for PYY from immediately prior to test-product consumption (t=0) to t=120 min following test-product consumption.
Measured: For 2 hours post intervention
Gastric Emptying Rate/Transit Time via Acetaminophen
Incremental area under the curve (iAUC) for acetaminophen from immediately prior to test-product consumption (t=0) to t=120 min following test-product consumption.
Measured: Oral dose of acetaminophen with blood samples taken for 2 hours post intervention
Change in Perceived Satiety Levels
The change in perceived satiety levels measured using the Motivation to Eat visual analogue scale (VAS) from immediately prior to test-product consumption (t=0) to t=120 min following test-product consumption.
Measured: For 2 hours post intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start2 Feb 2026
- Primary completion16 Apr 2026
- Study completion16 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Satiety in Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Olipop, PBC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- INQUIS Clinical Research
- Responsible party
- Sponsor
- Investigators
- Janice Campbell, Study director, INQUIS Clinical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07362563
- Sponsor's protocol ID
- INQ-2534
- Status last verified
- Jul 2026
- First submitted
- 9 Jan 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of 3 Different Prebiotic Sodas on Postprandial Levels of GLP-1, PYY, Transit Time and Satiety Levels: An Acute, Randomized Controlled Pilot Study in Healthy Participants
- ClinicalTrials.gov ID
- NCT07362563
- Acronym / sponsor ID
- INQ-2534
- Conditions
- Satiety in Healthy Volunteers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Olipop, PBCIndustry (pharma, biotech, devices)
- Collaborators
- INQUIS Clinical Research
- Study start
- 2 Feb 2026 (actual)
- Primary completion
- 16 Apr 2026 (actual)
- Study completion
- 16 May 2026 (actual)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to evaluate the acute effects of prebiotic sodas on postprandial levels of glucagon-like peptide-1 (GLP-1), peptide YY (PYY), gastric emptying, and satiety levels in healthy adults.
Detailed description
The primary aim of this clinical trial is to evaluate the effects of single-dose prebiotic sodas on on postprandial levels of GLP-1.
Participants (n=15) will be healthy males and healthy, non-pregnant, non-lactating females aged 18-60 years. Participants will consume a single dose of 3 different prebiotic sodas (6 - 9 g dietary fiber and 4 g total sugar per can) and one control soda (0 g dietary fiber and 4 g total sugar per can) in a randomized, crossover design over a period of 4-12 weeks with an interval of at least 1 week and at most 3 weeks between visits.
Secondary outcomes will include evaluating the effects of single-dose consumption of the control and prebiotic sodas on postprandial PYY, gastric emptying, and satiety levels.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control Soda | Placebo comparator | Other: Control SodaParticipants will consume one 12 oz can of a control soda |
| Prebiotic Soda - Shelf Stable | Experimental | Other: Prebiotic Soda - Shelf StableParticipants will consume one 12 oz can of the shelf stable prebiotic soda |
| Prebiotic Soda - Refrigerated | Experimental | Other: Prebiotic Soda - RefrigeratedParticipants will consume one 12 oz can of the refrigerated prebiotic soda |
| Prebiotic Soda - Shelf Stable + Functional Ingredient | Experimental | Other: Prebiotic Soda - Shelf Stable + Functional IngredientParticipants will consume one 12 oz can of the shelf stable prebiotic soda with an added functional ingredient |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Adults aged 18-60 years, inclusive.
- BMI between 18.0 and 30.0 kg/m2.
- Stable weight in the last 3 months (+/-5kg).
- Willing to abstain from unusual strenuous exercise, consuming alcoholic drinks and from taking fiber supplements for 24 hours before study days.
- Willing to refrain from smoking tobacco or e-cigarettes, and using marijuana in any form for 12h before and during study visits.
Key exclusion criteria (11 listed)
- Self-reported pregnant or breastfeeding women.
- Subjects with a history of severe food allergies or an allergy to acetaminophen.
- Known history of diabetes, any gastrointestinal disorder that alters the absorption of nutrients, liver disease, or the presence of any health condition, illness or drug use that increases risk to the subject or to others or may affect the results, as judged by the Qualified Investigator (QI).
- Subjects who are currently or in the last 2 months have been on oral or injectable GLP-1 receptor agonist (RA) medications.
- Subjects who consume more than 14 alcoholic drinks per week, or more than 5 alcoholic drinks on any one occasion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Control SodaParticipants will consume one 12 oz can of a control soda that contains 0 g dietary fiber and 4 g total sugar. | Other | Control Soda |
| Prebiotic Soda - Shelf StableParticipants will consume one 12 oz can of a shelf stable prebiotic soda that contains 6 g dietary fiber and 4 g total sugar. | Other | Prebiotic Soda - Shelf Stable |
| Prebiotic Soda - RefrigeratedParticipants will consume one 12 oz can of a shelf stable prebiotic soda that contains 9 g dietary fiber and 4 g total sugar. | Other | Prebiotic Soda - Refrigerated |
| Prebiotic Soda - Shelf Stable + Functional IngredientParticipants will consume one 12 oz can of a shelf stable prebiotic soda that contains 6 g dietary fiber, 4 g total sugar, and an added functional ingredient. | Other | Prebiotic Soda - Shelf Stable + Functional Ingredient |
Primary outcome
Blood GLP-1 iAUC
Time frame: For 2 hours post intervention
Incremental area under the curve (iAUC) for GLP-1 from immediately prior to test-product consumption (t=0) to t=120 min following test-product consumption.
3 secondary outcomes
Blood PYY iAUC
Time frame: For 2 hours post intervention
Gastric Emptying Rate/Transit Time via Acetaminophen
Time frame: Oral dose of acetaminophen with blood samples taken for 2 hours post intervention
Change in Perceived Satiety Levels
Time frame: For 2 hours post intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Satiety in Healthy Volunteers
Recruiting
Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Chronic Study
Healthy Participants, Healthy Adult Subject
Recruiting
Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Acute Postprandial Study
Healthy Participants, Healthy Adult Subject
Active, not recruiting
Effects of Pulse Consumption, Gut Microbiome, and Appetite in Healthy Participants
Microbial Colonization, Metabolic Syndrome
Enrolling by invitation
Impact of Energy Density on Energy Intake During Bed Rest
Bed Rest, Space Analogue
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janice Campbell study director
INQUIS Clinical Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prebiotic Soda - Shelf Stable, Prebiotic Soda - Refrigerated and Prebiotic Soda - Shelf Stable + Functional Ingredient in people with Satiety in Healthy Volunteers, run by Olipop, PBC at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood GLP-1 iAUC (time frame: For 2 hours post intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.